To go off topic a bit more too. The
reason I trust Michael is because I've checked his references and they check out. He knows where to extrapolate and where he can't. However, I'd like to see what he would say about the study I quoted below...
Michael said:
No supplement has ever shown a demonstrable increase in maximum LS in normal, healthy, well-cared-for organisms -- ie, relative to a control group with mean & max LS of >900 & 1200 days, respectively, in mice. By contrast, this is routinely achieved in modern CR studies.
Well -- it seems, by my cursory evaluation, there might be evidence to suggest otherwise
Life Sci. 1997;61(11):1037-44.
Treatment with L-deprenyl prolongs life in elderly dogs.Ruehl WW, Entriken TL, Muggenburg BA, Bruyette DS, Griffith WC, Hahn FF.
Deprenyl Animal Health, Overland Park, KS 66210, USA.
Eighty two beagle dogs ranging in age from 2.8 to 16.4 years and in weight from 6.3 to 15.8 kg were allotted to 41 pairs and administered placebo or 1 mg/kg L-deprenyl orally once daily for 2 years and 10 weeks. When survivorship for all dogs in the study was analyzed there was no significant difference between the L-deprenyl and placebo treated groups, most likely due to the (expected) survival of virtually all young dogs in both groups for the duration of the study. To assess whether L-deprenyl treatment begun in later life might enhance canine longevity in a fashion similar to that documented in rodents we also examined survival in a subset of elderly dogs who were between the ages of 10 and 15 yrs at the start of tablet administration and who received tablets for at least 6 months. In this subset, dogs in the L-deprenyl group survived longer (p < 0.05) than dogs in the placebo group. Twelve of 15 (80%) dogs in the L-deprenyl group survived to the conclusion of the study, in contrast to only 7 of 18 (39%) of the dogs who received placebo (P=0.017). Furthermore, by the time the first L-deprenyl treated dog died on day 427, 5 placebo treated dogs had already succumbed, the first on day 295. Specifically with respect to dogs, the findings reported herein suggest daily oral administration of 1 mg/kg L-deprenyl prolongs life when begun in relatively healthy dogs 10-15 years of age and maintained for the duration of the individual's life, but in any event for no less than six months.
PMID: 9307048 [PubMed - indexed for MEDLINE]
This study is a JOKE if you ask me. Deprenyl Animal Health -- THAT's a biased group if you asked me. It's like if I started the "supplment x acid Animal Health" group and published data to say the dogs lived an extra SIX months longer w/R-lipoc acid...I'd check how much extra cash the supplement x lobby stuck in my pocket if I were you...
Here's where I think that study went wrong (ALL kinds of bias -- in selection and otherwise -- to support their conclusion):
http://bmj.bmjjourna...ull/323/7303/42Education and debate
Systematic reviews in health care
Assessing the quality of controlled clinical trials
This is the first in a series of four articles
Peter Jüni, research fellow a, Douglas G Altman, professor of statistics in medicine b, Matthias Egger, senior lecturer in epidemiology and public health medicine c.
a Department of Social and Preventive Medicine, University of Bern, Bern, 3012 Switzerland, b Imperial Cancer Research Fund Medical Statistics Group, Centre for Statistics in Medicine, Institute of Health Sciences, Oxford OX3 7LF, c Medical Research Council Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol BS8 2PR
Correspondence to: M Egger m.egger@bristol.ac.uk
The quality of controlled trials is of obvious relevance to systematic reviews. If the "raw material" is flawed then the conclusions of systematic reviews cannot be trusted. Many reviewers formally assess the quality of primary trials by following the recommendations of the Cochrane Collaboration and other experts. 1 2 However, the methodology for both the assessment of quality and its incorporation into systematic reviews and meta-analysis are a matter of ongoing debate.3-5 In this article we discuss the concept of study quality and the methods used to assess quality.
Components of internal and external validity of controlled clinical trials
Internal validity---extent to which systematic error (bias) is minimised in clinical trials
* Selection bias: biased allocation to comparison groups
* Performance bias: unequal provision of care apart from treatment under evaluation
* Detection bias: biased assessment of outcome
* Attrition bias: biased occurrence and handling of deviations from protocol and loss to follow up
* External validity---extent to which results of trials provide a correct basis for generalisation to other circumstances
* Patients: age, sex, severity of disease and risk factors, comorbidity
* Treatment regimens: dosage, timing and route of administration, type of treatment within a class of treatments, concomitant treatments
* Settings: level of care (primary to tertiary) and experience and specialisation of care provider
* Modalities of outcomes: type or definition of outcomes and duration of follow up
Summary points
Empirical studies show that inadequate quality of trials may distort the results from systematic reviews and meta-analyses
The influence of the quality of included studies should routinely be examined in systematic reviews and meta-analyses
The use of summary scores from quality scales is problematic---it is preferable to examine the influence of key components of methodological quality individually
Based on empirical evidence and theoretical considerations, the generation and concealment of the allocation sequence, blinding, and handling of patient attrition in the analysis should always be assessed
Edited by nootropikamil, 25 August 2006 - 09:54 AM.